Emmanuel J. Ramos

FDA investigator

Appears on 9 documents from 2017 to 2021, mostly at sites in New Jersey. Most often cites production record review (21 CFR 211.192).

9
Documents on file
4.0
Observations per 483
2017
First seen
2021
Most recent

What they cite most

From 41 observations

Activity by year

2017: 1, 2018: 1, 2019: 5, 2020: 1, 2021: 1

Where

New Jersey 6 · India 2 · North Carolina 1

Is Emmanuel J. Ramos coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

9 documents, newest first
FirmOpen
483 Imprimis NJOF, -LLCJan 29, 2021 · Ledgew.ood, New Jersey
483 Aurolife Pharma LLCFeb 12, 2020 · Dayton, New Jersey
483 Aurobindo Pharma LimitedSep 27, 2019 · Polepally, India
483 Aurobindo Pharma Limited Unit VII, Formulation Plant, Plot §-1Sep 27, 2019 · Polepally, India
483 Water-Jel Technologies, LLCAug 15, 2019 · Huntersville, North Carolina
483 LTS Lohmann Therapy Systems Corp.Jun 11, 2019 · West Caldwell, New Jersey
483 Spectrum Laboratory Products IncMar 12, 2019 · New Brunswick, New Jersey

About this profile

What does Emmanuel J. Ramos inspect?

Emmanuel J. Ramos appears on 9 documents on file covering 8 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.100 and 21 CFR 211.67.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Emmanuel J. Ramos is dated Jan 29, 2021.